PSIL-002

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

PSIL-002 is a non-hallucinogenic serotonin 5-HT 1 receptor modulator which is under development for the treatment of depressive disorders, mood disorders, neurodegenerative disorders, and substance-related disorders. Its route of administration is unspecified. The drug's effects in animals have been described. PSIL-002 is being developed by Psilera. As of August 2022, it is in the preclinical research stage of development for all indications. The drug is an analogue of dimethyltryptamine (DMT), but its exact chemical structure does not yet seem to have been disclosed.

PSIL-002 is a non-hallucinogenic serotonin 5-HT 1 receptor modulator which is under development for the treatment of depressive disorders, mood disorders, neurodegenerative disorders, and substance-related disorders. Its route of administration is unspecified. The drug's effects in animals have been described. PSIL-002 is being developed by Psilera. As of August 2022, it is in the preclinical research stage of development for all indications. The drug is an analogue of dimethyltryptamine (DMT), but its exact chemical structure does not yet seem to have been disclosed.

See also

PSIL-001 List of investigational hallucinogens and entactogens List of investigational antidepressants

References

External links

Asset Pipeline - Psilera

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372045029 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.